Bethany Baird, APRN
Nurse Practitioner · Henderson, NVNPI 1306481031
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.7% of the total across 351 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 41 manufacturers reported payments, led by Daiichi Sankyo Inc. at 31.5% of the total. 2025 is the largest year on record at $3,210, more than ten times the $157 reported in 2021. Among nurse practitioner clinicians in NV with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 351 payments — averaging $17.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$2K
- Novartis$435
- Johnson & Johnson$397
- AstraZeneca$335
- Pfizer$251
- Sobi, Inc$222
- plus $3K from 35 others
What the payments were for
- Food & beverage$5,93895%
- Education$3305%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 165 | $1,973 |
| Novartis | 23 | $435 |
| Johnson & Johnson | 14 | $397 |
| AstraZeneca | 16 | $335 |
| Pfizer | 16 | $251 |
| Sobi, Inc | 13 | $222 |
| Bristol Myers Squibb | 9 | $214 |
| Lilly USA, LLC | 2 | $213 |
| Foundation Medicine, Inc. | 3 | $203 |
| Exelixis Inc. | 7 | $191 |
| AbbVie | 7 | $157 |
| Merck | 6 | $144 |
| Genentech USA, Inc. | 6 | $137 |
| Incyte Corporation | 5 | $123 |
| Beone Medicines USA, Inc. | 7 | $118 |
| Astellas Pharma US Inc | 5 | $95 |
| Eisai Inc. | 4 | $86 |
| Bayer | 3 | $69 |
| Geron Corporation | 3 | $67 |
| Genmab U.S., Inc. | 3 | $66 |
| Viiv Healthcare Company | 2 | $62 |
| Array Biopharma Inc | 4 | $61 |
| Regeneron Healthcare Solutions, Inc. | 3 | $58 |
| Gilead | 2 | $56 |
| Sanofi | 1 | $53 |
| Amgen | 2 | $49 |
| Coherus Oncology, Inc. | 2 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $39 |
| Sumitomo Pharma America, Inc. | 2 | $38 |
| Stemline Therapeutics Inc. | 2 | $37 |
| Beigene USA, Inc. | 1 | $33 |
| Karyopharm Therapeutics Inc. | 1 | $32 |
| Avyxa Pharma, LLC | 1 | $24 |
| GSK | 1 | $24 |
| Seagen Inc. | 1 | $22 |
| Dendreon Pharmaceuticals LLC | 1 | $21 |
| Spectrum Pharmaceuticals Inc. | 1 | $20 |
| EMD Serono, Inc. | 1 | $20 |
| Novocure Inc. | 1 | $18 |
| Inogen, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Enhertu$156
- FOUNDATIONONE$148
- FOUNDATIONONE HEME$148
- FOUNDATIONONE CDX$148
- FOUNDATIONFOCUS$148
- FOUNDATIONONE LIQUID CDX$148
- DARZALEX$115
How this compares
$6,269 in reported general payments places this provider in the 90th percentile of 933 nurse practitioner providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 26 | $20,157 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $512 |
| Pregabalin | 15 | $476 |
| Levothyroxine Sodium | 43 | $357 |
| Oxycodone Hcl | 16 | $302 |
| Cephalexin | 21 | $292 |
| Nystatin | 13 | $282 |
| Ondansetron Hcl | 13 | $259 |
| Gabapentin | 27 | $233 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 33 | $216 |
| Letrozole | 19 | $200 |
| Dexamethasone | 13 | $172 |
| Prednisone | 18 | $143 |
| Alprazolam | 17 | $133 |
| Famotidine | 13 | $124 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $251 | $20,15726 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 933 nurse practitioner providers in Nevada.
Other nurse practitioner in Henderson
- Charina TosteHenderson$393K
- Marites PilapilHenderson$11K
- Jackie ArmijoHenderson$11K
- Arianny Perrino LanzHenderson$9K
- Natalie HuxtableHenderson$7K
- Tiffany ShowHenderson$7K
- Stefanie RemsonHenderson$7K
- Melanie SpeedLas Vegas$80K
- Shelley MilesLas Vegas$34K
- Nasslynne LenzLas Vegas$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.